CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY

Their core work

CHU Nancy is a major French university hospital in the Grand Est region that contributes clinical expertise and patient cohorts to European immunology and transplantation research. Their H2020 involvement centers on understanding immune-mediated diseases — from post-transplant viral infections to autoimmune conditions like atopic dermatitis and ulcerative colitis. They bring real-world clinical data, biological samples, and medical knowledge to large multi-partner research consortia focused on precision medicine and treatment response prediction.

What they specialise in

How they've shifted over time

CHU Nancy's earliest H2020 engagement (2018, TRACE) was narrowly focused on adoptive T-cell transfer for transplant patients — a specialized clinical immunotherapy application. By 2019-2020, their participation shifted decisively toward broader immune-mediated disease research, incorporating systems biology tools like single-cell genomics, multi-omics, and computational modeling (3TR, ImmUniverse). This evolution reflects a move from intervention-focused transplant medicine toward data-driven precision immunology and disease stratification.

CHU Nancy is moving toward data-intensive, multi-omics approaches to understanding treatment non-response in immune diseases — expect future involvement in precision medicine and biomarker discovery consortia.

How they like to work

CHU Nancy participates exclusively as a partner, never as coordinator, which is typical for a clinical site contributing patient data and medical expertise to researcher-led consortia. Their projects involve large consortia (112 unique partners across 18 countries), indicating comfort operating within complex, multi-site European collaborations. They function as a clinical anchor — the kind of partner you recruit when you need a hospital with the right patient populations and clinical infrastructure.

With 112 unique consortium partners across 18 countries, CHU Nancy has built a broad European network primarily through large-scale health research projects. Their geographic reach spans most of the EU, though their connections are concentrated in Western European clinical and academic research hubs.

What sets them apart

CHU Nancy offers something many research-only institutions cannot: direct access to clinical patient cohorts for immune-mediated diseases, including transplant recipients and patients with inflammatory skin and gut conditions. As a major regional university hospital, they combine clinical practice with research capacity, making them a credible partner for translational projects that need real patient data. Their location in the Grand Est region also provides access to a cross-border patient population near Germany, Luxembourg, and Belgium.

Highlights from their portfolio

• 3TR
  Largest project by funding (EUR 825,031) investigating molecular mechanisms of treatment non-response across multiple autoimmune diseases — a flagship precision medicine consortium.
• ImmUniverse
  Targets the tissue microenvironment in atopic dermatitis and ulcerative colitis using multi-omics, representing CHU Nancy's move into systems-level disease understanding.
• TRACE
  Focused on a highly specialized niche — adoptive T-cell transfer for transplant patients with viral infections — demonstrating deep clinical immunotherapy expertise.